Fourth-quarter revenue fell 3 percent to $17.6 billion. Adjusted earnings per share were 66 cents, compared with an average analyst estimate of 63 cents per share, according to Bloomberg.
For the full year 2026, Pfizer expects earnings per share of $2.80 to $3.00 and revenue of $59.5 billion to $62.5 billion.
